Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 7,259 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,259 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total transaction of $234,102.75. Following the completion of the transaction, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $5,964,540.75. This trade represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Chi also recently made the following trade(s):

• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
• On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total transaction of $380,688.00.
• On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total value of $166,500.00.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $0.09 during midday trading on Thursday, reaching $30.10. 8,470,645 shares of the company traded hands, compared to its average volume of 9,937,356. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The stock’s 50-day simple moving average is $24.28 and its 200-day simple moving average is $20.80. The firm has a market cap of $6.58 billion, a PE ratio of 69.91 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the firm posted ($0.04) EPS. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its holdings in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC grew its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC increased its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of Hims & Hers Health in the second quarter valued at about $111,000. Finally, Quarry LP lifted its position in Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after buying an additional 2,913 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HIMS shares. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus target price of $21.43.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.